A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia.
X-linked immunodeficient (xid) (CBA/N female x DBA/2 male) F1 male mice, when treated with cyclophosphamide, were much more susceptible to challenge with aerosolized Pseudomonas aeruginosa serotype 11 than were control F1 female littermates. Mortality of F1 males was decreased significantly after intravenous administration of human P. aeruginosa serotype 11 O-specific monoclonal antibody. Antibody treatment reduced bacterial titers in the lungs as well as the severity of Pseudomonas-induced lung histopathology.
Zweerink
H J
HJ
Department of Immunology Research, Merck Sharp & Dohme Research Laboratories, Rahway, NJ 07065.
Detolla
L J
LJ
Gammon
M C
MC
Hutchison
C F
CF
Puckett
J M
JM
Sigal
N H
NH
D000818:Animals; D000907:Antibodies, Bacterial / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D007116:Immunization, Passive; D007275:Injections, Intravenous; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008297:Male; D051379:Mice; D009503:Neutropenia / Q000150:complications; D011014:Pneumonia / Q000517:prevention & control*; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa / Q000276:immunology*
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D003520:Cyclophosphamide